• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Revolution Medicines Inc.

    2/26/25 4:44:42 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RVMD alert in real time by email
    S-8 1 d930835ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 26, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Revolution Medicines, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-2029180

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    700 Saginaw Drive

    Redwood City, California

      94063
    (Address of Principal Executive Offices)   (Zip Code)

    2020 Incentive Award Plan

    2020 Employee Stock Purchase Plan

    (Full Title of the plan)

    Mark A. Goldsmith, M.D., Ph.D.

    President and Chief Executive Officer

    Revolution Medicines, Inc.

    700 Saginaw Drive

    Redwood City, California 94063

    (650) 481-6801

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Mark V. Roeder, Esq.

    John C. Williams, Esq.

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, California 94025

    (650) 328-4600

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”). The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this Registration Statement, Revolution Medicines, Inc. is sometimes referred to as “Registrant.”

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by the Registrant, relating to (a) 9,294,831 shares of its common stock, $0.0001 par value (the “Common Stock”), issuable to eligible employees, directors and consultants of the Registrant under the Registrant’s 2020 Incentive Award Plan (the “2020 Plan”) and (b) 1,858,966 shares of Common Stock issuable to eligible employees of the Registrant under the 2020 Employee Stock Purchase Plan (the “ESPP”). Shares available for issuance under the 2020 Plan and the ESPP were previously registered on registration statements on Form S-8 filed with the Commission on February 18, 2020, Registration No.  333-236493, March 2, 2021, Registration No.  333-253791, February 28, 2022, Registration No.  333-263098, February 27, 2023, Registration No.  333-270065, and February 26, 2024, Registration No.  333-277368 (the “Prior Registration Statements”). The Prior Registration Statements are currently effective. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate to and is submitted in accordance with Section E of the General Instructions to Form S-8 regarding Registration of Additional Securities. Pursuant to Section E of the General Instructions to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

     

    Item 3.

    Incorporation of Documents by Reference.

    The following documents filed with the Commission by the Registrant are incorporated by reference into this Registration Statement:

     

      •  

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 26, 2025; and

     

      •  

    the description of the Registrant’s Common Stock that is registered under Section 12 of the Exchange Act, in the Registrant’s registration statement on Form 8-A, filed on February 6, 2020, including any amendments or reports filed for the purpose of updating such description.

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the Registration Statement that indicates that all of the shares of Common Stock registered hereunder have been sold or that deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or Current Report on Form 8-K furnished under Items 2.02 or 7.01, and exhibits furnished on such form


    that relate to such items, that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information furnished under Items 2.02 or 7.01 of any Current Report on Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

    Item 5.

    Interests of Named Experts and Counsel.

    Certain attorneys affiliated with Latham & Watkins LLP own shares of the Registrant’s Common Stock representing in the aggregate less than 1% of the outstanding shares of the Registrant’s Common Stock.

     

    Item 8.

    Exhibits.

     

    Exhibit

    Number

            Incorporated by Reference   

    Filed
    Herewith

      

    Exhibit Description

      

    Form

      

    Date

      

    Number

    4.1    Amended and Restated Certificate of Incorporation.    8-K    2/18/2020    3.1   
    4.2    Amended and Restated Bylaws.    8-K    3/8/2021    3.1   
    4.3    Form of Common Stock Certificate.    S-1    1/17/2020    4.2   
    5.1    Opinion of Latham & Watkins LLP.             X
    23.1    Consent of Independent Registered Public Accounting Firm.             X
    23.2    Consent of Latham & Watkins LLP (included in Exhibit 5.1).             X
    24.1    Power of Attorney. Reference is made to the signature page to the Registration Statement.             X
    99.1#    2020 Incentive Award Plan.    S-1/A    2/3/2020    10.7(a)   
    99.2#    2020 Employee Stock Purchase Plan.    S-1/A    2/3/2020    10.8   
    107.1    Filing Fee Table.             X

     

    #

    Indicates management contract or compensatory plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, California, on this 26th day of February, 2025.

     

    Revolution Medicines, Inc.
    By:  

    /s/ Mark A. Goldsmith

      Mark A. Goldsmith, M.D., Ph.D.
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark A. Goldsmith, M.D., Ph.D., Jeff Cislini and Jack Anders, and each of them acting individually, as his true and lawful attorneys-in-fact and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature    Title   Date

    /s/ Mark A. Goldsmith

    Mark A. Goldsmith, M.D., Ph.D.

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      February 26, 2025

    /s/ Jack Anders

    Jack Anders

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      February 26, 2025

    /s/ Elizabeth McKee Anderson

    Elizabeth McKee Anderson

       Director   February 26, 2025

    /s/ Flavia Borellini

    Flavia Borellini, Ph.D.

       Director   February 26, 2025

    /s/ Alexis Borisy

    Alexis Borisy

       Director   February 26, 2025

    /s/ Frank Clyburn

    Frank Clyburn

       Director   February 26, 2025

    /s/ Sandra J. Horning

    Sandra J. Horning, M.D.

       Director   February 26, 2025

    /s/ Lorence Kim

    Lorence Kim, M.D.

       Director   February 26, 2025

    /s/ Sushil Patel

    Sushil Patel, Ph.D.

       Director   February 26, 2025

    /s/ Thilo Schroeder

    Thilo Schroeder, Ph.D.

       Director   February 26, 2025

    /s/ Barbara Weber

    Barbara Weber, M.D.

       Director   February 26, 2025
    Get the next $RVMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVMD

    DatePrice TargetRatingAnalyst
    11/18/2025$75.00Outperform
    Wolfe Research
    11/3/2025$77.00Outperform
    RBC Capital Mkts
    10/21/2025$90.00Outperform
    Mizuho
    10/16/2025$85.00Buy
    Stifel
    9/12/2025$72.00Strong Buy
    Raymond James
    9/5/2025$99.00Buy
    Truist
    8/19/2025$75.00Overweight
    Piper Sandler
    8/15/2025$67.00Overweight
    Wells Fargo
    More analyst ratings

    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Revolution Medicines with a new price target

    Wolfe Research initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $75.00

    11/18/25 8:26:23 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RBC Capital Mkts initiated coverage on Revolution Medicines with a new price target

    RBC Capital Mkts initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $77.00

    11/3/25 9:08:29 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Revolution Medicines with a new price target

    Mizuho initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $90.00

    10/21/25 7:22:03 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

    REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET. To listen to a live webcast of this event, or access an archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company's website for at least 14

    2/4/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

    REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor. The first-in-human trial, RMC-5127-001 [NCT07349537], is an open-label trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of RMC-5127 as both a monotherapy and in combination settings. The trial will enroll patients with RAS G12V–mutated solid tumors, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC),

    1/29/26 8:00:00 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

    Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapyFirst Breakthrough Therapy Designation for an investigational drug specifically targeting KRAS G12D mutation in NSCLCRevolution Medicines' third RAS(ON) inhibitor to receive this designation REDWOOD CITY, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the

    1/8/26 8:00:00 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Goldsmith Mark A exercised 24,010 shares at a strike of $0.54, increasing direct ownership by 10% to 256,479 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    2/10/26 5:30:31 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    General Counsel Cislini Jeff sold $104,965 worth of shares (908 units at $115.60), decreasing direct ownership by 2% to 46,976 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    1/23/26 4:31:05 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Operating Officer Horn Margaret A exercised 75,000 shares at a strike of $38.47 and sold $7,542,023 worth of shares (75,000 units at $100.56) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    1/9/26 4:20:44 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.

    SCHEDULE 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/10/26 11:19:49 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.

    SCHEDULE 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/9/26 8:53:14 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    1/7/26 4:23:03 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    12/9/24 4:15:16 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    11/8/24 10:52:39 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/14/24 6:30:27 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    2/14/24 9:26:21 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Financials

    Live finance-specific insights

    View All

    Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

    Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line metastatic PDAC this yearDaraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug Designation and a Commissioner's National Priority VoucherNew leadership appointments strengthened global development and commercialization capabilitiesRevolution Medicines to hold webcast today at 4:30 p

    11/5/25 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

    REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live

    10/29/25 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

    Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasibCompany entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercializationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicte

    8/6/25 4:02:29 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RVMD
    Leadership Updates

    Live Leadership Updates

    View All

    Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

    REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. "I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "As a physician-

    9/29/25 9:00:15 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

    Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ

    12/15/22 7:00:00 AM ET
    $GERN
    $MRNA
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

    REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies. Dr. Kim will serve as an independent director for the remaining term of Neil Exter, who is stepping down after serving as a director most recently since 2019

    7/13/22 7:00:00 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care